An approach to the nutritional management of autism

Alternative Therapies in Health and Medicine

Volumn 9, Issue 5, 2003, Pages 22-32+126

  Kidd, Parris M ^a  

^a INNOVISION COMMUNICATIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBIOTIC AGENT; ASCORBIC ACID; CALCIUM; CARNITINE; COPPER; CYANOCOBALAMIN; DIMETHYLGLYCINE; DOPAMINE; ESSENTIAL FATTY ACID; EXCITOTOXIN; FOLIC ACID; INOSITOL; MAGNESIUM; MINERAL; NICOTINAMIDE; PTERIN DERIVATIVE; PYRIDOXINE; RETINOL; SECRETIN; SEROTONIN; TERATOGENIC AGENT; VITAMIN; VITAMIN K GROUP; ZINC;

AUTISM; BEHAVIOR TERATOLOGY; CONSTIPATION; DETOXIFICATION; DEVELOPMENTAL DISORDER; DIARRHEA; DIET THERAPY; DIGESTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE PREDISPOSITION; FOOD ALLERGY; GASTROINTESTINAL INFECTION; GENETIC PREDISPOSITION; HUMAN; METABOLIC DISORDER; MINERAL BLOOD LEVEL; NUTRITION; NUTRITIONAL INTOLERANCE; REVIEW; RISK FACTOR; VITAMIN BLOOD LEVEL;

AUTISTIC DISORDER; COMPLEMENTARY THERAPIES; DIET; DIETARY SUPPLEMENTS; FOOD HABITS; FOOD PREFERENCES; HUMANS; MICRONUTRIENTS; PRIMARY HEALTH CARE; RISK FACTORS; TRACE ELEMENTS;

EID: 0141708054     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217-250.
2. Treffert DA, Wallace GL. Islands of genius. Sci Amer. 2002;June:76-85.
3. Kidd PM. Autism, an extreme challenge to integrative medicine. Part 1. The knowledge base. Altern Med Rev. 2002;7:292-316.
4. Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2. Medical management. Altern Med Rev. 2002;7:472-499.
5. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J Autism Dev Disorders. 2000;31:569-576.
6. Blaylock RL. The central role of excitotoxicity in autism spectrum disorders. JANA J Am Natur Assoc. 2003;6:10-22
7. Bryson SE, Smith IM. Epidemiology of autism: prevalence, associated characteristics, and implications for research and service delivery. Ment Retard Dev Disabil Res Rev. 1998;4:97-103.
8. Rimland B. The autism epidemic, vaccinations, and mercury. J Nutr Environ Med. 2000;10:261-266.
9. Fiona JS, Baron-Cohen S, Bolton P, others. Brief report: prevalence of autism spectrum conditions in children aged 5-11 years in Cambridgeshire, UK. Autism. 2002;6:231-237.
10. Baker HC. A comparison study of autism spectrum disorder referrals 1997 and 1989. J Autism Dev Disord. 2002;32:121-125.
11. Hobson RP, Bishop M. The pathogenesis of autism: insights from congenital blindness; Philos Trans R Soc Lond B Biol Sci. 2003 Feb 28;358(1430):335-44.
12. Rosenhall U, Nordin V, Sandstrom M, Ahlsen G, Gillberg C. Autism and hearing loss. J Autism Dev Disord. 1999 Oct;29(5):349-57.
13. Prater CD, Zylstra RG. Autism: a medical primer. Am Fam Physician. 2002 Nov 1;66(9):1667-74. Review.
14. Coleman M, Gillberg C. The Biology of the Autistic Syndromes. New York:Praeger;1985.
15. Korvatska E, Van de Water J, Anders TF, et al. Genetic and immunologic considerations in autism. Neurobiol Disease 2002:9:107-125. Erratum in: Neurobiol Dis. 2002 Jun;10(1):69.
16. Boddart N, Zilbovicius M. Functional neuroimaging and childhood autism. Pediatr Radiol. 2002;32:1-7.
17. Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Am Phys Surgs. 2003;8:6-11.
18. Acosta MT, Pearl PL. The neurobiology of autism: new pieces of the puzzle. Curr Neurol Neurosci Rep. 2003 Mar:3(2):149-56. Review.
19. Rutter M. Autism: Two-way interplay between research and clinical work. J Child Psychol Psychiatr Allied Discipl. 1999;40:169-188.
20. Cuccaro ML, Shao Y, Bass MP, Abramson RK, Ravan SA, Wright HH, Wolpert CM, Donnelly SL, Pericak-Vance MA. Behavioral comparisons in autistic individuals from multiplex and singleton families. J Autism Dev Disord. 2003 Feb;33(1):87-91.
21. Rimland B. Infantile Autism. New York: Appleton-Century-Crofts; 1964.
22. Rodier PM. The Early Origins of Autism. Sci Amer 2000;Feb:56-63.
23. Pangborn J. Autism: pertinent laboratory tests. In: Rimland B, ed. DAN! (Defeat Autism Now!) 2001 Advanced Practitioner Training. San Diego, CA: Autism Research Institute; 2002.
24. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull. 2001;56:479-485.
25. Warren RP, Singh VK. Elevated serotonin levels in autism: association with the major histocompatibility complex. Neuropsychobiol. 1996;34:72-75.
26. Garreau B, Barthelemy C, Jouve J, Bruneau N, Muh JP, Lelord G. Urinary homovanillic acid levels of autistic children. Dev Med Child Neurol. 1988 Feb;30(1):93-8.
27. Autism Research Institute (ARI), 4182 Adams Avenue, San Diego, CA 92116, USA; 2002. www.autismresearchinstitute.com
28. DAN! (Defeat Autism Now!). Conference proceedings, consensus reports, medical assessment protocols. Autism Research Institute, San Diego, CA 92116, USA;2002. www.autismresearchinstitute.com
29. Baker SM. Clinical strategies in autism. In: Rimland B, ed. DAN! (Defeat AutismNow!) Spring 2002 Conference Practitioner Training. San Diego, CA: Autism Research Institute;2002. www.autismresearchinstitute.com
30. Shattock P, Whiteley P. The Sunderland Protocol: A Logical Sequencing of Biomedical Interventions for the Treatment of Autism and Related Disorders. Sunderland, UK: Autism Research Unit, University of Sunderland; 2000.
31. Reichelt KL, Ekrem J, Scott H. Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J Appl Nutr. 1990;42:1-11.
32. Gillberg IC, Gillberg C. Autism in immigrants: a population-based study from Swedish rural and urban areas. J Intellect Disabil Res. 1996;40:24-31.
33. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 1979;2:174-177.
34. Gillberg C. The role of the endogenous opioids in autism and possible relationships to clinical features. In: Wing L, ed. Aspects of Autism: Biological Research. London, UK: Gaskell/NAS; 1988.
35. Wakefield AJ, Puleston JM, Montgomery SM, et al. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002;16:663-674.
36. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders - is it worth another look? Med Hypotheses. 2002;58:422-428.
37. Baker SM. Part II: Notes on treatment options. In: Pangborn JB, Baker SM, eds. Biomedical Assessment Options for Children with Autism and Related Problems. San Diego, CA: Autism Research Institute; 2000.
38. Pangborn J. Autism: metabolic differentiation, role of DPPIV/CD26, some pertinent lab tests. In: Rimland B, ed. DAN! (Defeat Autism Now!) Spring 2002 Conference. San Diego, CA: Autism Research Institute; 2002.
39. DeFelice KL. Enzymes for Autism and Other Neurological Conditions: A Practical Guide; 2002.
40. Laidler JR. DAN! Mercury Detoxification Consensus Group. DAN! (Defeat Autism Now) Mercury Detoxification Consensus Group Position Paper. San Diego, CA: Autism Research Institute; 2001.
41. Vogelaar A. Studying the effects of essential nutrients and environmental factors on autistic behavior. DAN! (Defeat Autism Now!) Think Tank. San Diego, CA: Autism Research Institute; 2000.
42. Adams JB, Dinelli L, Fabes R, et al. Effect of Vitamin/Mineral Supplements on Children with Autism. Tempe, AZ: Arizona State University, College of Engineering and Applied Sciences; 2002.
43. Rimland B. The use of vitamin B6, magnesium, and DMG in the treatment of autistic children and adults. In: Shaw W, ed. Biological Treatments for Autism and PDD. Lenexa, KS: The Great Plains Laboratory, Inc.; 2002.
44. Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. J Child Neurol. 1988;3:S68-S72
45. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27-44.
46. Kleijnen J, Knipschild P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991;29:931-941.
47. Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16:169-173.
48. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29:191-194.
49. Kirkman Laboratories. The Kirkman Guide to Intestinal Health in Autism Spectrum Disorders. Lake Oswego, OR: Kirkman Laboratories; 2002.
50. Wilcken DE, Wilcken B. B vitamins and homocysteine in cardiovascular disease and aging. Ann N Y Acad Sci 1998;854:361-370.
51. Froster-Iskenius U, Bodeker K, Oepen T, others. Folic acid treatment in males and females with fragile-(X)-syndrome. Am J Med Genet 1986;23:273-289.
52. Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Progr Neuropsychopharmacol Biol Psychiatry 1993;17:765-774.
53. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167:1600-1619.
54. Johnson S. Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease? Med Hypotheses. 2001;56:641-645.
55. Walsh W. Metallothionein promotion therapy in autism spectrum disorders. In: Rimland B, ed. DAN! (Defeat Autism Now!) Spring 2002 Conference Practitioner Training. San Diego, CA: Autism Research Institute; 2002.
56. Coyle P, Philcox JC, Carey LC, other. Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002;59:627-647.
57. Wainwright PE. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002;61:61-69.
58. Willatts P, Forsyth JS. The role of long-chain polyunsaturated fatty acids in infant cognitive development. Prostaglandins Leukot Essent Fatty Acids 2000;63:95-100.
59. Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2000;63:1-9.
60. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001;65:1-7.
61. Hardy PM, Hardy SM. Omega-3 fatty acids in the pathophysiology and treatment of autism. In: Rimland B, ed. DAN! (Defeat Autism Now!) Spring 2002 Conference. San Diego, CA: Autism Research Institute; 2002.
62. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000;54:979-983.
63. Bradstreet J, Kartzinel J. Biological interventions in the treatment of autism and PDD. In: Rimland B, ed. DAN! (Defeat Autism Now!) Fall 2001 Conference. San Diego, CA: Autism Research Institute; 2001.
64. Ellaway C, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol 1999;14:162-167.
65. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997;39:313-318.
66. Levine J, Aviram A, Holan A, et al. Inositol treatment of autism. J Neural Transm 1997;104:307-310.
67. Pangborn JB, Baker SM, eds. Biomedical Assessment Options for Children with Autism and Related Problems. San Diego, CA: Autism Research Institute; 2000.
68. D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 1996;85:1076-1079.
69. Great Smokies Diagnostic Laboratory. Comprehensive Digestive Stool Analysis (CDSA) Test. 63 Zillicoa street, Asheville, NC 28801, USA; 2003. www.gsdl.com
70. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-642.
71. McQueen JM, Heck AM. Secretin for the treatment of autism. Ann Phrmacother 2002;36:305-311
72. Holmes A. Heavy metal toxicity in autistic spectrum disorders. Mercury toxicity. In: Rimland B, ed. DAN! (Defeat Autism Now!) Fall 2001 Conference Practitioner Training. San Diego, CA: Autism Research Institute; 2002.
73. O'Reilly BA, Waring RH. Enzyme and sulphur oxidation deficiencies in autistic children with known food/chemical intolerances. J Orthomol Med 1993;8:198-200.
74. Alberti A, Pirrone P, Elia M, others. Sulphation deficit in "low-functioning" autistic children: a pilot study. Biol Psychiatr 1999;46:420-424.
75. Kirkman Laboratories. Detoxification of heavy metals in the treatment of autism. In: A Guide to Scientific Nutrition for Autism and Related Conditions. Lake Oswego, OR: Kirkman Laboratories;2002.
76. Rapp DJ. Is This Your Child's World? New York, NY: Bantam Books;1996.
77. Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000;30:475-479.
78. Singh VK, Warren RP, Odell D, et al. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 1991;61:448-455.
79. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunology 2001;120:170-179.
80. Connolly AM, Chez MG, Pestronk A, et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 1999;134:607-613.
81. Burger RA, Warren RP. Possible immunogenetic basis for autism. Ment Retard Dev Disabil Res Rev 1998;4:137-141.
82. Singh VK, Warren RP, Odell JD, et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 1993;7:97-103.
83. Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy 1996;9:143-147.